Private company

HOOKIPA Pharma Inc.

Last updated Oct 19, 2026.

Overview

$43.9MRevenue, fiscal 2024²

-$43.5MNet income, fiscal 2024³

IndustryPharmaceutical Preparations¹
HeadquartersNew York, New York¹
Incorporated inDE⁴
Business address350 Fifth Avenue, 72Nd Floor, Suite 7240, New York, Ny 10118⁴
Filer categoryNon-accelerated filer, Smaller reporting company⁴

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on our proprietary arenavirus platform that is designed to target and amplify T cell and immune responses to fight diseases. Our replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. We believe that our technologies can meaningfully leverage the human immune system therapeutic purposes by inducing CD8+ T cell response levels previously not achieved by other immune therapy approaches.⁵ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-117.1%Operating margin²

-99.0%Net margin³

118.3%Revenue growth, 2024²

-84.9%Return on equity²

-$77.2MFree cash flow²

Where the money goes

Where each dollar of revenue went, fiscal 2024

Research and development

Research and development100¢$68.5M
Income tax0¢$106.0K

Out of $43.9M in revenue.²³ The company lost money this year.

Financial statements

Revenue⁶⁷⁸⁹²$43.9M in 2024+476% since 2018

Operating income¹⁰⁶⁷⁸⁹²-$51.5M in 2024+263% since 2017

Net income¹⁰⁶⁷⁸⁹²³-$43.5M in 2024+242% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023	2024
Revenue		$7.6M⁶	$11.9M⁷	$19.6M⁸	$18.4M⁹	$14.2M²	$20.1M²	$43.9M²
Research and development	$9.8M¹⁰	$22.0M⁶	$46.3M⁷	$54.8M⁸	$82.9M⁹	$68.6M²	$86.4M²	$68.5M²
Operating expenses					$100.1M⁹	$87.4M²	$117.8M²	$95.4M²
Operating income	-$14.2M¹⁰	-$21.2M⁶	-$51.1M⁷	-$53.3M⁸	-$81.7M⁹	-$73.2M²	-$97.7M²	-$51.5M²
Interest	$606.0K¹⁰	$778.0K⁶	$877.0K⁷	$786.0K⁸	$898.0K⁹	$687.0K⁹	$317.0K⁹
Income before tax					-$75.7M⁹	-$64.7M²	-$81.2M²	-$43.6M²
Income tax	$4.0K¹⁰	$24.0K⁶	$0⁷	$0⁸	$1.0K⁹	$230.0K²	$368.0K²	-$106.0K²
Net income	-$12.7M¹⁰	-$16.2M⁶	-$43.0M⁷	-$44.1M⁸	-$75.7M⁹	-$64.9M²	-$81.6M²	-$43.5M³
Earnings per share			-$2.41⁷	-$1.69⁸	-$2.30⁹	-$9.91²	-$8.63²	-$3.47²
Earnings per share (diluted)			-$2.41⁷	-$1.69⁸	-$2.30⁹	-$9.91²	-$8.63²	-$3.47²
Shares (weighted, basic)					32.8M shares⁹	6.6M shares²	9.5M shares²	12.5M shares²
Shares (weighted, diluted)					32.8M shares⁹	6.6M shares²	9.5M shares²	12.5M shares²

Total assets¹⁰⁶⁷⁸⁹²$82.5M in 2024+21% since 2018

Total liabilities¹⁰⁶⁷⁸⁹²$31.3M in 2024+31% since 2018

Shareholders’ equity⁶⁷⁸⁹²$51.2M in 2024

Cash⁶¹⁰⁷⁸⁹²$39.7M in 2024−35% since 2017

Long-term debt¹⁰⁶⁷⁸⁹$1.2M in 2023−84% since 2019

Fiscal year	2017	2018	2019	2020	2021	2022	2023	2024
Cash	$61.4M⁶	$48.6M¹⁰	$113.2M⁶	$142.7M⁷	$65.9M⁸	$112.5M⁹	$117.1M²	$39.7M²
Receivables					$6.9M⁸	$6.5M⁹	$511.0K²	$290.0K²
Current assets		$62.3M¹⁰	$128.0M⁶	$171.5M⁷	$102.1M⁸	$147.2M⁹	$147.1M²	$80.7M²
Property, plant and equipment					$16.4M⁸	$18.0M⁹	$7.7M²	$179.0K²
Total assets		$68.3M¹⁰	$143.7M⁶	$187.8M⁷	$126.0M⁸	$170.5M⁹	$161.3M²	$82.5M²
Accounts payable					$8.8M⁸	$5.5M⁹	$12.5M²	$8.7M²
Current liabilities		$14.7M¹⁰	$14.8M⁶	$21.1M⁷	$27.7M⁸	$35.6M⁹	$42.0M²	$24.7M²
Long-term debt			$7.3M¹⁰	$6.6M⁶	$6.1M⁷	$2.9M⁸	$1.2M⁹
Long-term liabilities					$8.8M⁸	$32.3M⁹	$29.5M²	$6.7M²
Total liabilities		$23.9M¹⁰	$25.8M⁶	$31.7M⁷	$36.5M⁸	$67.9M⁹	$71.5M²	$31.3M²
Retained earnings					-$222.8M⁸	-$287.7M⁹	-$369.3M²	-$412.8M²
Shareholders’ equity	-$42.7M⁶	-$60.4M⁷	$117.9M⁸	$156.1M⁹	$89.6M²	$102.5M²	$89.9M²	$51.2M²

Cash from operations¹⁰⁶⁷⁸⁹²-$77.0M in 2024+546% since 2017

Capital spending¹⁰⁶⁷⁸⁹²$194.0K in 2024−85% since 2017

Free cash flow¹⁰⁶⁷⁸⁹²-$77.2M in 2024+484% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023	2024
Cash from operations	-$11.9M¹⁰	-$15.0M⁶	-$41.7M⁷	-$39.3M⁸	-$66.0M⁹	-$20.0M²	-$57.5M²	-$77.0M²
Depreciation and amortization					$4.6M⁹	$3.6M²	$3.6M²	$2.8M²
Stock-based compensation					$7.6M⁹	$5.0M²	$2.3M²	$2.0M²
Capital spending	$1.3M¹⁰	$2.1M⁶	$2.0M⁷	$2.4M⁸	$12.6M⁹	$5.0M²	$4.2M²	$194.0K²
Free cash flow	-$13.2M	-$17.1M	-$43.7M	-$41.7M	-$78.6M	-$25.0M	-$61.7M	-$77.2M
Cash from investing					-$12.6M⁹	-$5.0M²	-$4.2M²	-$194.0K²
Cash from financing					-$235.0K⁹	$72.3M²	$65.7M²	-$1.3M²

Compare HOOKIPA Pharma Inc. with another company

Leadership

Who has led HOOKIPA Pharma Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chief financial officer

Chief operating officer

Christine D. Baker2022–2023

20202025

Chief executive officerMalte Peters Jul 24, 2024 to now¹⁴
Chief executive officerJorn Aldag Apr 17, 2019 to Jul 24, 2024¹⁵
Chief financial officerMary Theresa Coelho Jul 24, 2024 to now¹⁶
Chief financial officerReinhard Kandera Apr 17, 2019 to Jul 24, 2024¹⁷
Chief operating officerChristine D. Baker Jul 1, 2022 to Apr 18, 2023¹⁸

Board members and other officers (20)

Chief Development OfficerMark Winderlich Apr 11, 2024 to now¹⁹
Chief Medical OfficerKatia Schlienger Apr 18, 2023 to Apr 18, 2023²⁰
Chief Business OfficerChristine D. Baker Mar 22, 2021 to Apr 20, 2022²¹
Sr. VP, Technical DevelopmentAnders Lilja Apr 17, 2019 to Jan 27, 2020²²
Chief Scientific OfficerDavid Pinschewer Apr 17, 2019 to Apr 24, 2019²³
Chief Medical OfficerIgor Matushansky Apr 17, 2019 to Jul 1, 2022²⁴
Sr. VP, ResearchKlaus Orlinger Apr 17, 2019 to now²⁵
Chief Technology OfficerRoman Necina Nov 19, 2019 to now²⁶
Board memberSean A. Cassidy Jul 24, 2024 to now²⁷
Board memberMary Theresa Coelho Apr 4, 2023 to now²⁸
Board memberMalte Peters Apr 18, 2023 to now²⁹
Board memberJean-Charles Soria Oct 23, 2020 to Jun 4, 2021³⁰
Board memberChristoph Lengauer Apr 17, 2019 to Jun 4, 2021³¹
Board memberDavid Ross Kaufman Apr 17, 2019 to now³²
Board memberDeventer Sander Van Apr 17, 2019 to Oct 23, 2020³³
Board memberGraziano Seghezzi Apr 17, 2019 to Jun 14, 2021³⁴
Board memberJorn Aldag Apr 17, 2019 to now¹⁵
Board memberJulie O'Neill Apr 17, 2019 to now³⁵
Board memberMichael Aaron Kelly Apr 17, 2019 to Jul 1, 2022³⁶
Board memberReinhard Kandera Apr 17, 2019 to now¹⁷

Timeline

Jul 24, 2024New chief executive Malte Peters becomes CEO¹⁴
Apr 17, 2019New chief executive Jorn Aldag becomes CEO¹⁵

Filings

216 filings to the SEC since October 2021: 6 annual reports, 11 quarterly reports, 55 major events, 67 insider forms, 24 large holders, 53 other. The latest 20:

Oct 9, 20254 EDGAR
Aug 27, 2025144/A EDGAR
Aug 27, 2025144 EDGAR
Aug 8, 202515-12G EDGAR
Jul 29, 2025EFFECT EDGAR
Jul 29, 2025EFFECT EDGAR
Jul 29, 202525 EDGAR
Jul 29, 2025S-8 POS EDGAR
Jul 29, 2025S-8 POS EDGAR
Jul 29, 2025S-8 POS EDGAR
Jul 29, 2025S-8 POS EDGAR
Jul 29, 2025POS AM EDGAR
Jul 29, 2025POS AM EDGAR
Jul 29, 20258-K EDGAR
Jul 23, 20254 EDGAR
Jul 23, 20254 EDGAR
Jul 18, 20258-K EDGAR
Jul 7, 2025UPLOAD EDGAR
Jul 3, 2025DEFM14A EDGAR
Jun 30, 2025CORRESP EDGAR

The 216 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 7 buys and 4 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Aug 19, 2025	Peters MalteChief Executive Officer	Sale	25,172	$0.82	$20.6K	Form 4
Jul 22, 2025	Peters MalteChief Executive Officer	Sale	29,176	$0.92	$26.8K	Form 4
Jul 22, 2025	Coelho Mary TheresaEVP and CFO	Sale	13,609	$0.92	$12.5K	Form 4
Aug 21, 2023	Kandera ReinhardChief Financial Officer	Buy	7,000	$0.73	$5.1K	Form 4
Aug 16, 2023	Kandera ReinhardChief Financial Officer	Buy	8,000	$0.71	$5.7K	Form 4
Jul 11, 2023	Aldag JornChief Executive Officer	Buy	5,000	$0.83	$4.2K	Form 4
Jul 7, 2023	Aldag JornChief Executive Officer	Buy	5,000	$0.81	$4.0K	Form 4
Jul 5, 2023	Aldag JornChief Executive Officer	Buy	5,000	$0.89	$4.5K	Form 4
Jul 3, 2023	Aldag JornChief Executive Officer	Buy	5,000	$0.89	$4.5K	Form 4
Jun 30, 2023	Kandera ReinhardChief Financial Officer	Buy	12,000	$0.88	$10.6K	Form 4
Dec 21, 2021	Matushansky IgorChief Medical Officer	Sale	14,949	$2.49	$37.2K	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

EcoR1 Capital, LLCSCHEDULE 13G/A, 6 filings Apr 8, 2022 to Feb 14, 2025³⁷
SOFINNOVA CAPITAL VI FCPRSCHEDULE 13D/A, 2 filings Feb 13, 2023 to Feb 14, 2025³⁸
Invus Global Management, LLCSC 13G/A, 1 filing Aug 2, 2024³⁹
Artal International S.C.A.SC 13G, 1 filing Jul 8, 2024⁴⁰
BAKER BROS. ADVISORS LPSC 13D, 3 filings Feb 14, 2023 to Jun 14, 2024⁴¹
Redmile Group, LLCSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 2024⁴²
FMR LLCSC 13G/A, 4 filings Feb 9, 2022 to Sep 11, 2023⁴³
Knoll Capital Management, LLCSC 13G, 1 filing Jun 20, 2023⁴⁴
Deep Track Capital, LPSC 13G/A, 2 filings Mar 4, 2022 to Feb 14, 2023⁴⁵
Forbion Capital Fund II Cooperatief U.A.SC 13G/A, 1 filing Feb 11, 2022⁴⁶

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARHOOKIPA Pharma Inc. filings on SEC EDGAR
2
SEC EDGARHOOKIPA Pharma Inc. 10-K for fiscal 2024
3
SEC EDGARHOOKIPA Pharma Inc. 10-K for fiscal 2024
4
SEC EDGARHOOKIPA Pharma Inc. filings on SEC EDGAR
5
SEC EDGARHOOKIPA Pharma Inc. annual report, Item 1 (Business)
6
SEC EDGARHOOKIPA Pharma Inc. 10-K for fiscal 2018
7
SEC EDGARHOOKIPA Pharma Inc. 10-K for fiscal 2019
8
SEC EDGARHOOKIPA Pharma Inc. 10-K for fiscal 2020
9
SEC EDGARHOOKIPA Pharma Inc. 10-K for fiscal 2021
10
SEC EDGARHOOKIPA Pharma Inc. 10-K for fiscal 2017
11
SEC EDGARHOOKIPA Pharma Inc. 10-Q for fiscal 2024
12
SEC EDGARHOOKIPA Pharma Inc. 10-Q for fiscal 2024
13
SEC EDGARHOOKIPA Pharma Inc. 10-Q for fiscal 2024
14
SEC EDGARMalte Peters, Chief executive officer
15
SEC EDGARJorn Aldag, Chief executive officer
16
SEC EDGARMary Theresa Coelho, Chief financial officer
17
SEC EDGARReinhard Kandera, Chief financial officer
18
SEC EDGARChristine D. Baker, Chief operating officer
19
SEC EDGARMark Winderlich, Chief Development Officer
20
SEC EDGARKatia Schlienger, Chief Medical Officer
21
SEC EDGARChristine D. Baker, Chief Business Officer
22
SEC EDGARAnders Lilja, Sr. VP, Technical Development
23
SEC EDGARDavid Pinschewer, Chief Scientific Officer
24
SEC EDGARIgor Matushansky, Chief Medical Officer
25
SEC EDGARKlaus Orlinger, Sr. VP, Research
26
SEC EDGARRoman Necina, Chief Technology Officer
27
SEC EDGARSean A. Cassidy, Board member
28
SEC EDGARMary Theresa Coelho, Board member
29
SEC EDGARMalte Peters, Board member
30
SEC EDGARJean-Charles Soria, Board member
31
SEC EDGARChristoph Lengauer, Board member
32
SEC EDGARDavid Ross Kaufman, Board member
33
SEC EDGARDeventer Sander Van, Board member
34
SEC EDGARGraziano Seghezzi, Board member
35
SEC EDGARJulie O'Neill, Board member
36
SEC EDGARMichael Aaron Kelly, Board member
37
SEC EDGAREcoR1 Capital, LLC SCHEDULE 13G/A on HOOKIPA Pharma Inc.
38
SEC EDGARSOFINNOVA CAPITAL VI FCPR SCHEDULE 13D/A on HOOKIPA Pharma Inc.
39
SEC EDGARInvus Global Management, LLC SC 13G/A on HOOKIPA Pharma Inc.
40
SEC EDGARArtal International S.C.A. SC 13G on HOOKIPA Pharma Inc.
41
SEC EDGARBAKER BROS. ADVISORS LP SC 13D on HOOKIPA Pharma Inc.
42
SEC EDGARRedmile Group, LLC SC 13G/A on HOOKIPA Pharma Inc.
43
SEC EDGARFMR LLC SC 13G/A on HOOKIPA Pharma Inc.
44
SEC EDGARKnoll Capital Management, LLC SC 13G on HOOKIPA Pharma Inc.
45
SEC EDGARDeep Track Capital, LP SC 13G/A on HOOKIPA Pharma Inc.
46
SEC EDGARForbion Capital Fund II Cooperatief U.A. SC 13G/A on HOOKIPA Pharma Inc.